Unknown PHASE2 INTERVENTIONAL 1-arm NCT04517539

Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors

Sponsor: Shanghai Cancer Hospital, China

Interventions rhGM-CSF，Peginterferon alfa-b2，radiation

Updated 5 times since 2020 Last updated: Aug 16, 2020 Started: Dec 1, 2020 Primary completion: Dec 1, 2022 Completion: Dec 10, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Thymic Epithelial Tumor, this trial is ongoing. The trial is conducted by Shanghai Cancer Hospital, China and has accumulated 5 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Not Yet Recruiting PHASE2
Sep 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Cancer Hospital, China

Data source: Shanghai Cancer Hospital, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China